Amoxicillin Capsule Batch with a Non-Compendial UV Assay
A 52-year-old woman returns to a community pharmacy in Cebu City with four capsules from a newly delivered batch of amoxicillin 500 mg capsules (batch AMX-2506, expiry 2027-05). She says the capsules feel light and two are only partly filled. The pharmacy has a UV-Vis spectrophotometer, a certified amoxicillin reference standard, and pH 6.8 phosphate buffer, but no HPLC. The owner performs a triplicate in-house assay: dissolve capsule contents, filter, dilute, measure absorbance at 272 nm, and compare with a standard; mean result is 91.8% of label (RSD 1.1%). The distributor's certificate of analysis reports 99.2% by the compendial HPLC method. The pharmacy's internal release limit is 95.0–105.0% of label; the pharmacopeial assay limit for amoxicillin capsules is 90.0–120.0%. The remaining stock is 38 boxes. The owner asks whether to release, quarantine, or return the batch, and whether to report it.
1. Should the in-house UV-Vis result be used to release or reject batch AMX-2506? Explain the analytical and regulatory reasoning.
Read the worked answer
No. A UV-Vis measurement at 272 nm is not specific enough for a capsule assay unless it has been validated against the compendial HPLC method. Capsule excipients, capsule shell components, and amoxicillin degradation products can absorb at the same wavelength, so a result of 91.8% may be falsely low or falsely high. The good RSD (1.1%) shows precision, not accuracy. The batch cannot be released on this result, and it should not be rejected solely on it either: the correct status is quarantine pending confirmatory HPLC by an FDA-accredited laboratory or the supplier. The supplier's 99.2% CoA is also not a substitute for the pharmacy's own release decision. Under GMP and RA 10918 quality expectations, release must be based on the compendial method or a properly validated alternative.
2. If the pharmacy wanted to use UV-Vis as an alternative assay, outline the validation plan and acceptance criteria, and explain why specificity is critical.
Read the worked answer
Validation should include: specificity-no interference from placebo, capsule shell, known degradants and stressed samples; linearity over 80–120% of the assay concentration (r ≥ 0.999); accuracy by recovery (98–102%); repeatability (RSD ≤ 2%) and intermediate precision; LOD/LOQ; range; robustness (pH, filter type, time, temperature). The UV method should be compared side-by-side with HPLC on the same samples. Specificity is the critical parameter because the whole release decision depends on the absorbance being due only to amoxicillin. If a degradant or excipient contributes, the method is invalid regardless of precision. Until such validation is complete and approved, UV remains a screening tool, not a release method.
3. What immediate patient-safety and documentation actions should the pharmacist take?
Read the worked answer
Immediate actions: quarantine all 38 boxes, label as do not dispense, retain the returned capsules and packaging, and document the complaint and assay. Do not dispense remaining stock. Contact the distributor or manufacturer for a replacement and a full CoA with chromatograms; send a sample for confirmatory testing. File a quality defect or adverse event report with FDA Philippines if the batch is confirmed out of specification or if the patient has taken it. Advise the patient to return remaining capsules and to contact her prescriber if she has taken subpotent doses; document the counseling. Check whether other batches from the same supplier are affected.